Tiotropium: A novel anticholinergic for the once-daily treatment of COPD

Formulary

Volumn 39, Issue 4, 2004, Pages 203-212

  Jeffery, Sean M ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; LONG ACTING DRUG; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; SALMETEROL; TIOTROPIUM BROMIDE;

ABDOMINAL PAIN; ACCIDENT; CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; DISSOCIATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSPNEA; EDEMA; EPISTAXIS; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG FUNCTION; MYALGIA; PHARYNGITIS; RASH; REVIEW; RHINITIS; SIDE EFFECT; SINUSITIS; THORAX PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; XEROSTOMIA;

EID: 2042417382     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349:1436-1442.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504.
3. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. The GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 200;163(5):1256-1276.
4. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): a consensus statement of the European Respiratory Society. Eur Respir J 1995;8:1398-1420.
5. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: ATS statement. Am J Respir Crit Care Med. 1995;152:S77-S121.
6. Group of the Standards of Care Committee of the British Thoracic Society. Guidelines for the management of chronic obstructive pulmonary disease. Thorax. 1997;52;S1-S28.
7. Chapman KR. History of anticholinergic treatment in airways disease. In: Gross NJ, ed. Anticholinergic Therapy in Obstructive Airways Disease. London: Franklin Scientific Publications; 1993:9-17.
8. Herxheimer H. Atropine cigarettes in asthma emphysema. BMJ. 1959;2:167.
9. Witek TJ, Disse B. Inhaled anticholinergic therapy: applied pharmacology and interesting developments. Curr Opin Invest Drugs. 2001;2:53-58.
10. Disse B, Reichl R, Speck G, et al. BA 679 BR, a novel, long-acting anticholinergic bronchodilator. Life Sci. 1993;52:537-544.
11. Takahashi T, Belvisi M, Patel H, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med. 1994;150:1640-1645
12. O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med. 1996;154:876-880
13. Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999;64:457-464.
14. Maesen F, Smeets JJ, Costongs M, et al. Ba 679 BR, a new long-acting antimuscarinic bronchodilator: A pilot dose-escalation study in COPD. Eur Respir J. 1993;6:1031-1036.
15. van Noord JA, Bantje TA, Eland ME, et al, and the Dutch Tiotropium Study Group. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax. 2000;55:289-294.
16. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1136-1142.
17. Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124:1743-1748.
18. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.
19. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J. 2002;19:200-216.
20. 1. The Lung Health Study. JAMA. 1994;272:1497-1505.
21. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122:47-55.
22. Gold WM. Pulmonary function testing. In: Murray, Nadel, eds. Textbook of Respiratory Medicine. 3rd ed. Available at: http://home.mdconsult.com/das/book/22506689/view/919. Accessed October 3, 2002.
23. Guyton AC, Hall JE. Pulmonary Ventilation. In: Textbook of Medical Physiology. 10th ed. Philadelphia, Pa: WB Saunders; 2000:432-443.
24. Crapo JD. Respiratory structure and function. In: Goldman, ed. Cecil Textbook of Medicine. 21st ed. Available at: http://home.mdconsult.com/das/book/22502961/view/882. Accessed October 3, 2002.
25. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399-404.
26. Disse B, Rominger K, Serby CW et al. The pharmacokinetic (PK) profile of tiotropium during long-term treatment in stable COPD [abstract]. Am J Respir Crit Care Med. 1999;159 Suppl. 2:A524.
27. Calverley PM, Lee A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003;58:855-860.
28. Barnes PJ. The pharmacologic properties of tiotropium. Chest. 2000;117:63S-66S.
29. Spiriva HandiHaler [package insert]. Ridgefield, Conn: Boehringer Ingelheim; 2004.
30. Chodosh S, Flanders J, Serby CW, et al. Effective use of HandiHaler dry powder inhalation system over a range of COPD disease severity. J Aerosol Med. 2001;14:309-315.
31. Backer D, Ollgaard B, Gerken F, et al. Assessment of patient performance of the HandiHaler compared with the metered dose inhaler for weeks after instruction. Respir Med. 1997;10:1126-1133.